Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RLMD | 8-K | neutral | 4/10 | Relmada Therapeutics reported Q1 2026 results that were in line with its pre-revenue clinical-stage profile, with a net | May 12, 2026 |
| IKT | 8-K | neutral | 4/10 | Inhibikase Therapeutics reported Q1 2026 results with a net loss of $16.4M ($0.10/share), slightly wider than the $13.7M | May 12, 2026 |
| AIM | 8-K | bearish | 7/10 | AIM ImmunoTech closed a warrant exercise inducement transaction on May 8, 2026, receiving ~$3.6M in gross proceeds from | May 12, 2026 |
| XFOR | 8-K | neutral | 2/10 | X4 Pharmaceuticals held its 2026 annual meeting on May 11, 2026, where stockholders approved an amendment to the 2017 Eq | May 12, 2026 |
| RZLT | 8-K | neutral | 5/10 | Rezolute reported Q3 fiscal 2026 results with a net loss of $16.2M ($-0.16/share), narrower than the $18.9M loss ($-0.27 | May 12, 2026 |
| TXMD | 8-K | neutral | 4/10 | TherapeuticsMD reported Q1 2026 results: net income from continuing operations of $103K vs a net loss of $636K in Q1 202 | May 12, 2026 |
| ZNTL | 8-K | bullish | 7/10 | Zentalis reported Q1 2026 results with a net loss of $35.4M ($0.50/share), slightly better than the $0.52 consensus. The | May 12, 2026 |
| KURA | 8-K | neutral | 5/10 | Kura Oncology reported Q1 2026 results with $5.8M in KOMZIFTI product revenue (first full commercial quarter), beating c | May 12, 2026 |
| LCTX | 8-K | neutral | 3/10 | Lineage Cell Therapeutics reported Q1 2026 revenue of $1.7M (up 14.8% YoY from $1.5M) and a net loss of $4.8M ($0.02 bas | May 12, 2026 |
| PEPG | 8-K | neutral | 5/10 | PepGen reported Q1 2026 net loss of $17.8M ($-0.26/share), narrower than the $30.2M loss in Q1 2025, with cash of $132.3 | May 12, 2026 |
| ZNTL | PRESS-RELEASE | bullish | 7/10 | Zentalis reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with no revenue. The key catalyst is the s | May 12, 2026 |
| IBIO | PRESS-RELEASE | bearish | 6/10 | iBio reported Q3 FY2026 results with EPS of -$0.07 (GAAP) vs consensus -$0.06, a miss of ~16.7%. Revenue was $0, in line | May 12, 2026 |
| AVIR | PRESS-RELEASE | bearish | 5/10 | Atea Pharmaceuticals reported Q1 2026 EPS of -$0.57, a 2.7% miss vs consensus of -$0.56, with net loss widening to $45.4 | May 12, 2026 |
| RZLT | PRESS-RELEASE | neutral | 5/10 | Rezolute reported Q3 fiscal 2026 net loss of $16.2M ($0.16 per share), narrower than the $18.9M loss a year ago, with ca | May 12, 2026 |
| PHVS | PRESS-RELEASE | neutral | 5/10 | Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs €-0.85 a year ago, with cash of €247M extended by a | May 12, 2026 |
| CAPR | PRESS-RELEASE | neutral | 5/10 | Capricor Therapeutics reported Q1 2026 EPS of -$0.59, missing consensus of -$0.54 by ~9.3%, with no revenue. The key cat | May 12, 2026 |
| BOLT | PRESS-RELEASE | bearish | 7/10 | Bolt Biotherapeutics reported Q1 2026 EPS of -$4.31, missing consensus of -$3.60 by 19.7%, and collaboration revenue col | May 12, 2026 |
| LBRX | PRESS-RELEASE | neutral | 4/10 | LB Pharmaceuticals reported Q1 2026 EPS of -$0.67, in line with consensus of -$0.67, and a net loss of $19.1M vs $5.3M a | May 12, 2026 |
| SLDB | PRESS-RELEASE | bearish | 6/10 | Solid Biosciences reported Q1 2026 EPS of -$0.53, a 20.9% miss versus the -$0.44 consensus, with net loss widening to $5 | May 12, 2026 |
| MAZE | 8-K | neutral | 4/10 | Maze Therapeutics reported Q1 2026 results with a net loss of $24.2M ($0.45/share), narrower than the $32.8M loss in Q1 | May 12, 2026 |
| SLS | 8-K | neutral | 6/10 | SELLAS reported Q1 2026 results with a net loss of $8.4M ($-0.05 EPS) vs consensus $-0.06, a 16.7% beat. The key catalys | May 12, 2026 |
| VRCA | 8-K | neutral | 5/10 | Verrica reported Q1 2026 revenue of $5.0M (above $4.5M consensus) and a GAAP net loss of $0.45/share, beating the $-0.59 | May 12, 2026 |
| IMNM | 8-K | bullish | 7/10 | Immunome reported Q1 2026 results: net loss of $53.8M ($-0.48/share) vs consensus $-0.60, a beat of 20% on EPS. The NDA | May 12, 2026 |
| BOLT | 8-K | neutral | 3/10 | Bolt Biotherapeutics reported Q1 2026 collaboration revenue of $26,000, down 98% YoY from $1.2M, and a net loss of $7.2M | May 12, 2026 |
| MAZE | PRESS-RELEASE | mixed | 5/10 | Maze Therapeutics reported Q1 2026 net loss of $24.2M ($0.45/share), missing consensus of $0.43/share by 4.7%, with lice | May 12, 2026 |
| VRCA | PRESS-RELEASE | bullish | 7/10 | Verrica Pharmaceuticals reported Q1 2026 revenue of $5.0M (beat consensus of $4.5M by 11.6%) and GAAP EPS of -$0.45 (bea | May 12, 2026 |
| NKTX | PRESS-RELEASE | neutral | 4/10 | Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FD | May 12, 2026 |
| IKT | PRESS-RELEASE | mixed | 6/10 | Inhibikase reported a Q1 2026 net loss of $0.10 per share, slightly missing the $0.09 consensus, but operating expenses | May 12, 2026 |
| CRIS | 8-K | bearish | 7/10 | Curis reported Q1 2026 results with zero revenue (post-Erivedge sale) and a net loss of $24.2M, significantly worse than | May 12, 2026 |
| MOLN | 6-K | neutral | 5/10 | Molecular Partners reported Q1 2026 results showing a net loss of CHF 13.1M, improved from a CHF 16.8M loss in Q1 2025, | May 12, 2026 |